A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/27/2019
Start Date:July 4, 2017
End Date:March 3, 2022
Contact:Pfizer Pfizer CT.gov Call Center
Email:ClinicalTrials.gov_Inquiries@pfizer.com
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)

The purpose of this international, phase 2, open-label, response rate study of talazoparib is
to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic
castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy
and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone
acetate/prednisone).


Inclusion Criteria:

1. At least 18 years of age.

2. Histologically or cytologically confirmed adenocarcinoma of the prostate without
signet cell, or small cell features.

3. Patients must have measurable soft tissue disease per RECIST 1.1

4. DNA damage repair deficiency as assessed centrally by a gene mutation biomarker panel
(testing of de novo or archival tumor tissue (via central laboratory) or prior
historical testing (with Sponsor approval) using the Foundation Medicine,
FoundationOne CDx™ NGS gene panel test.

5. Consent to a saliva sample collection for a germline comparator, unless prohibited by
local regulations or ethics committee (EC) decision.

6. Serum testosterone ≤ 1.73 nmol/L (50 ng/dL) at screening.

7. Bilateral orchiectomy or ongoing androgen deprivation therapy with a
gonadotropin-releasing hormone (GnRH) agonist/antagonist (surgical or medical
castration).

8. Progressive disease at study entry defined as 1 or more of the following 3 criteria:

- A minimum of 3 rising PSA values with an interval of at least 1 week between
determinations. The screening central laboratory PSA value must be ≥ 2 μg/L (2
ng/mL) if qualifying solely by PSA progression.

- Soft tissue disease progression as defined by RECIST 1.1.

- Bone disease progression defined by PCWG3 with 2 or more new metastatic lesions
on bone scan.

9. Metastatic disease.

10. Previous treatment with 1 or 2 chemotherapy regimens including at least 1 taxane-based
regimen for metastatic (non castrate or castrate) prostate cancer. Patients may have
received radium-223 and/or cabazitaxel, or were deemed unsuitable, declined, or did
not have access to these therapies.

11. Documented disease progression (either radiographic or biochemical) on at least 1
novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the
treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate
prostate cancer or nonmetastatic (M0) CRPC.

12. Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before
day 1 for patients receiving these therapies.

13. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

14. Estimated life expectancy of ≥ 6 months as assessed by the investigator.

15. Able to swallow the study drug, have no known intolerance to study drugs or
excipients, and comply with study requirements.

16. Must use a condom when having sex from the time of the first dose of study drug
through 4 months after last dose of study drug. A highly effective form of
contraception must be used from the time of the first dose of study drug through 4
months after last dose of study drug when having sex with a non pregnant female
partner of childbearing potential.

17. Must agree not to donate sperm from the first dose of study drug to 4 months after the
last dose of study drug.

18. Patients must be willing and able to comply with scheduled visits, treatment plan,
laboratory tests and other study procedures.

Exclusion Criteria:

1. 1. Use of systemic chemotherapeutic (including but not limited to taxanes), hormonal,
biologic, or radionuclide therapy for treatment of metastatic prostate cancer (other
than approved bone targeting agents and GnRH agonist/antagonist) or any other
investigational agent within 4 weeks before day 1.

2. Prior treatment with a PARP inhibitor, cyclophosphamide, or mitoxantrone chemotherapy.
Patients who discontinued prior platinum based chemotherapy <=6 months prior to
screening or whose disease previously progressed on platinum based therapy at any time
in the past are also excluded.

3. Treatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within
4 weeks or 5 half lives of the drug (whichever is longer) before Day 1 and/or during
study participation

4. Radiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy)
before day 1.

5. Major surgery within 2 weeks before day 1.

6. Clinically significant cardiovascular disease.

7. Significant renal, hepatic, or bone marrow organ dysfunction.

8. Known or suspected brain metastasis or active leptomeningeal disease.

9. Symptomatic or impending spinal cord compression or cauda equina syndrome.

10. Prior diagnosis of myelodysplastic syndrome or acute myeloid leukemia

11. History of another cancer within 3 years before enrollment with the exception of
nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1
cancer that has a remote probability of recurrence in the opinion of the investigator
and the sponsor.

12. Gastrointestinal disorder affecting absorption.

13. Current or anticipated use within 7 days prior to first dose of study drug or
anticipated use during the study of the following P gp inhibitors (amiodarone,
carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin,
indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine,
ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar).

14. Any other acute or chronic medical or psychiatric condition (concurrent disease,
infection, or comorbidity) that interferes with ability to participate in the study,
causes undue risk, or complicates the interpretation of data, in the opinion of the
investigator or sponsor, including recent (within the past year) or active suicidal
ideation or behavior or laboratory abnormality that may increase the risk associated
with study participation or investigational product administration or may interfere
with the interpretation of study results and, in the judgment of the investigator,
would make the patient inappropriate for entry into this study.

15. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
patients who are Pfizer employees, including their family members, directly involved
in the conduct of the study.

16. Fertile male subjects who are unwilling or unable to use a highly effective method of
contraception as outlined in this protocol for the duration of the study and for at
least 4 months after the last dose of investigational product.
We found this trial at
56
sites
Atlanta, Georgia 30318
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1000 Blythe Blvd
Charlotte, North Carolina 28203
(704) 355-2000
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
1364 Clifton Rd NE
Atlanta, Georgia 30322
(404) 712-2000
Emory University Hospital As the largest health care system in Georgia and the only health...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28211
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
10628 Park Rd
Charlotte, North Carolina 28210
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28210
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28211
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
8800 North Tryon Street
Charlotte, North Carolina 28262
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28262
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28262
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Charlotte, North Carolina 28277
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Chula Vista, California 91911
?
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Chula Vista, California 91913
?
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Concord, North Carolina 28025
?
mi
from
Concord, NC
Click here to add this to my saved trials
Concord, North Carolina 28025
?
mi
from
Concord, NC
Click here to add this to my saved trials
Darlinghurst, New South Wales
?
mi
from
Darlinghurst,
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Edmonds, Washington 98026
?
mi
from
Edmonds, WA
Click here to add this to my saved trials
Edmonds, Washington 98026
?
mi
from
Edmonds, WA
Click here to add this to my saved trials
Fayetteville, Georgia 30214
?
mi
from
Fayetteville, GA
Click here to add this to my saved trials
Hampton, Virginia 23666
?
mi
from
Hampton, VA
Click here to add this to my saved trials
Issaquah, Washington 98029
?
mi
from
Issaquah, WA
Click here to add this to my saved trials
Issaquah, Washington 98029
?
mi
from
Issaquah, WA
Click here to add this to my saved trials
La Mesa, California 91942
?
mi
from
La Mesa, CA
Click here to add this to my saved trials
44151 15th Street West
Lancaster, California 93534
?
mi
from
Lancaster, CA
Click here to add this to my saved trials
Lincolnton, North Carolina 28092
?
mi
from
Lincolnton, NC
Click here to add this to my saved trials
Milwaukee, Wisconsin 53226
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Monroe, North Carolina 28112
?
mi
from
Monroe, NC
Click here to add this to my saved trials
Monroe, North Carolina 28112
?
mi
from
Monroe, NC
Click here to add this to my saved trials
823 82nd Parkway, Suite B
Myrtle Beach, South Carolina 29572
(843) 449-1010 ext.268
Carolina Urologic Research Center Carolina Urologic Research Center (CURC) has been recognized both nationally and...
?
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
5900 Lake Wright Dr
Norfolk, Virginia 23502
(757) 466-8683
Virginia Oncology Associates Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
101 The City Drive South
Orange, California 92868
714-456-7890
University of California, Irvine Medical Center We are UC Irvine Health. We are a devoted...
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
2222 East Highland Avenue
Phoenix, Arizona 85016
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rock Hill, South Carolina 29732
?
mi
from
Rock Hill, SC
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
7901 Frost Street
San Diego, California 92123
858-939-3400
Sharp Memorial Hospital Sharp Memorial Hospital offers clinical excellence with the latest technology and patient-centered...
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Santa Monica, California 90404
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tempe, Arizona 85284
?
mi
from
Tempe, AZ
Click here to add this to my saved trials
721 Clinic Drive
Tyler, Texas 75701
?
mi
from
Tyler, TX
Click here to add this to my saved trials